Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 2/20 | 0.46 |
| ▸ | CYP1A1 | P04798 | 1/20 | 0.46 |
| ▸ | CYP1B1 | Q16678 | 1/20 | 0.46 |
| ▸ | SLC6A4 | P31645 | 3/20 | 0.44 |
| ▸ | HTR2A | P28223 | 2/20 | 0.44 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.44 |
| ▸ | MAPT | P10636 | 3/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | CA12 | O43570 | 2/20 | 0.43 |
| ▸ | CA1 | P00915 | 2/20 | 0.43 |
| ▸ | CA2 | P00918 | 2/20 | 0.43 |
| ▸ | CA7 | P43166 | 2/20 | 0.43 |
| ▸ | CA9 | Q16790 | 2/20 | 0.43 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.43 |
| ▸ | CPS1 | P31327 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 2/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29590981 | 1.00 | CYP1A2 (0.46) | CYP1A2CYP1A1CYP1B1SLC6A4HTR2A | |
| SCHEMBL1042563 | 0.82 | MAPT (0.56) | CYP1A2CYP1A1CYP1B1SLC6A4HTR2A | |
| SCHEMBL18144205 | 0.79 | NFE2L2 (0.59) | CYP1A2CYP1A1CYP1B1APP | |
| SCHEMBL18144202 | 0.79 | NFE2L2 (0.59) | CYP1A2CYP1A1CYP1B1APP | |
| SCHEMBL29513208 | 0.78 | CA12 (0.50) | CYP1A2CYP1A1CYP1B1SLC6A4MAPT | |
| SCHEMBL254529 | 0.78 | CA12 (0.50) | CYP1A2CYP1A1CYP1B1SLC6A4MAPT | |
| SCHEMBL1145316 | 0.78 | SLC6A4 (0.54) | CYP1A2SLC6A4HTR2AKCNH2CA12 | |
| SCHEMBL29768449 | 0.78 | SLC6A4 (0.54) | CYP1A2SLC6A4HTR2AKCNH2CA12 | |
| SCHEMBL30954109 | 0.78 | GPR84 (0.43) | SLC6A4HTR2AKCNH2PPARGPPARA | |
| SCHEMBL320903 | 0.78 | GPR84 (0.43) | SLC6A4HTR2AKCNH2PPARGPPARA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 211 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117843683-A | Fluorene triangle macrocyclic eutectic material, preparation method and application thereof | 南京大学 | 2024-04-09 | — | — | CN | claimed |
| EP-4695241-A1 | THIADIAZOLONE DERIVATIVES, COMPOSITIONS AND USES THEREOF | Danatlas Pharmaceuticals Co., Ltd. (CN) | 2026-02-18 | — | — | EP | disclosed |
| US-20260034113-A1 | THIADIAZOLONE DERIVATIVES, COMPOSITIONS AND USES THEREOF | DANATLAS PHARMACEUTICALS CO LTD (CN) | 2026-02-05 | — | — | US | disclosed |
| CN-120152972-A | Thiadiazole derivative, composition and application thereof | 北京丹擎医药科技有限公司 | 2025-06-13 | — | — | CN | disclosed |
| WO-2025119195-A1 | COMBINATION OF POLQ INHIBITOR AND ANTI-CANCER THERAPEUTIC AGENT | DANATLAS PHARMACEUTICALS CO., LTD. (CN) | 2025-06-12 | — | — | WO | disclosed |
| CN-120077028-A | Thiadiazole derivative, composition and application thereof | 北京丹擎医药科技有限公司 | 2025-05-30 | — | — | CN | disclosed |
| US-20250145594-A1 | MODULATORS OF THE INTEGRATED STRESS PATHWAY | ABBVIE INC. | 2025-05-08 | — | — | US | disclosed |
| WO-2025021198-A1 | PolQ DEGRADERS, COMPOSITIONS AND USES THEREOF | DANATLAS PHARMACEUTICALS CO., LTD. (CN) | 2025-01-30 | — | — | WO | disclosed |
| WO-2024245310-A1 | THIAZOLYL OR THIADIAZOLYL AMIDES DERIVATIVES AND USE THEREOF | NINGBO NEWBAY TECHNOLOGY DEVELOPMENT CO., LTD. (CN) | 2024-12-05 | — | — | WO | disclosed |
| CN-118693282-B | Secondary battery and preparation method and application thereof | 蜂巢能源科技股份有限公司 | 2024-12-03 | — | — | CN | disclosed |
| US-20060094767-A1 | 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2006-05-04 | — | — | US | disclosed |
| US-20060084677-A1 | Quinoline derivatives as anti-inflammatory agents | BROKA CHRIS A | 2006-04-20 | — | — | US | disclosed |
| CN-1729159-A | Amide compounds and methods for controlling plant diseases | SUMITOMO CHEMICAL CO (JP) | 2006-02-01 | — | — | CN | disclosed |
| EP-1555267-A1 | 2,3-DIHYDRO-6-NITROIMIDAZO 2,1-b OXAZOLES | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2005-07-20 | — | — | EP | disclosed |
| WO-2005042542-A1 | 2,3-DIHYDRO-6-NITROIMIDAZO (2,1-B) OXAZOLE COMPOUNDS FOR THE TREATMENT OF TUBERCULOSIS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2005-05-12 | — | — | WO | disclosed |
| CN-1199950-C | Quinolene derivatives as anti-inflammation agents | HOFFMANN LA ROCHE (CH) | 2005-05-04 | — | — | CN | disclosed |
| CN-1466575-A | Quinoline derivatives as anti-inflammatory agents | - | 2004-01-07 | — | — | CN | disclosed |
| EP-1313707-A1 | QUINOLINE DERIVATIVES AS ANTI-INFLAMMATION AGENTS | F. HOFFMANN-LA ROCHE AG (CH) | 2003-05-28 | — | — | EP | disclosed |
| US-20020082276-A1 | Quinoline derivatives as anti-inflammatory agents | SNYTEX (U.S.A.) LLC | 2002-06-27 | — | — | US | disclosed |
| WO-2002012192-A1 | QUINOLENE DERIVATIVES AS ANTI-INFLAMMATION AGENTS | F. HOFFMANN-LA ROCHE AG (CH) | 2002-02-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060084677-A1 | Quinoline derivatives as anti-inflammatory agents | NR5A2, PTGER4, IL5 | CYP1A2 87/4885CYP1A1 178/4885CYP1B1 368/4885 |
| US-20060094767-A1 | 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles | NR2C2, NR4A3, NR4A2 | CYP1A2 659/4885CYP1A1 1394/4885CYP1B1 1052/4885 |
| US-20020082276-A1 | Quinoline derivatives as anti-inflammatory agents | CNR1, CNR2, PTGER4 | CYP1A2 38/4885CYP1A1 62/4885CYP1B1 99/4885 |
| US-20260034113-A1 | THIADIAZOLONE DERIVATIVES, COMPOSITIONS AND USES THEREOF | SRD5A2, NR3C2, SRD5A1 | CYP1A2 145/4885CYP1A1 213/4885CYP1B1 68/4885 |
| US-20250145594-A1 | MODULATORS OF THE INTEGRATED STRESS PATHWAY | ATF4, ATF1, DDIT3 | CYP1A2 1824/4885CYP1A1 2015/4885CYP1B1 2495/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.